A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
This study is investigating a new treatment called Sacituzumab Tirumotecan (Sac-TMT) for a type of bladder cancer that has spread or is advanced and hasn't responded well to previous treatments. We're looking to see if Sac-TMT can help people with this condition live longer than those receiving standard chemotherapy options like Vinflunine, Docetaxel, or Paclitaxel. This is a Phase 3 trial, which means it involves a larger group of people to confirm if the new medicine is effective and safe. The study aims to find new ways to help patients whose cancer has progressed after standard treatments, including immunotherapy and platinum-based chemotherapy.
Auf einen Blick
Worum geht es in dieser Studie?
This clinical trial is looking for a new treatment for a type of cancer that affects the bladder, called urothelial cancer. This is specifically for cases where the cancer has spread to other parts of the body (metastatic) or is advanced locally and can't be removed by surgery or treated with radiation. Currently, doctors use treatments like chemotherapy, immunotherapy, and targeted therapies for this kind of cancer. However, researchers are always trying to find even better options, especially for people whose cancer has unfortunately started to get worse after these standard treatments.
The new medicine being tested in this study is called Sacituzumab Tirumotecan, or Sac-TMT for short. The main goal of this study is to find out if Sac-TMT can help people live longer compared to existing chemotherapy treatments. Participants in this study will either receive Sac-TMT or one of the standard chemotherapy options, such as Vinflunine, Docetaxel, or Paclitaxel.
By comparing Sac-TMT with these established treatments, the researchers hope to understand if it offers a new and more effective way to manage advanced bladder cancer. This kind of research is very important for improving the care of patients in the future.
Wichtige Erkenntnisse
- This study is for advanced bladder cancer that has worsened after other treatments.
- It tests a new medicine called Sacituzumab Tirumotecan (Sac-TMT).
- Compares Sac-TMT to standard chemotherapy treatments.
- Aims to see if Sac-TMT helps people live longer.
- You would receive regular medical check-ups and monitoring.
- Die Teilnahme ist freiwillig, und Sie können jederzeit zurücktreten.
Wer könnte berechtigt sein?
To join this study, you would need to have specific types of advanced urothelial (bladder) cancer that can be measured by doctors. Your cancer must also have started to get worse after you've already had certain treatments, including immunotherapy, platinum-based chemotherapy, and a medicine called enfortumab vedotin. Most people can only have had up to two previous lines of treatment for their cancer.
Your general health also needs to be good enough to take part. This includes having a good 'performance status' (meaning you're able to carry out most daily activities without too much trouble) and your organs functioning well. The research team will check all these details carefully to make sure the study is a safe and suitable option for you.
There are also some reasons why you might not be able to join. For example, if you have certain severe eye conditions or other significant uncontrolled health problems, you might not be eligible. The hospital team will discuss all these points with you to determine if this study is the right fit.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Do I have advanced bladder cancer that has spread or is locally advanced?
- Has my cancer started to get worse after prior treatments (including immunotherapy, platinum chemotherapy, and enfortumab vedotin)?
- Have I had no more than two previous lines of cancer treatment?
- Am I generally in good health and able to carry out daily activities?
- Are my organs (like kidneys and liver) working well?
- Do I have any severe eye conditions, as this might prevent me from joining?
Was beinhaltet die Teilnahme?
If you decide to take part in this study, you would be randomly assigned to receive either the new medicine, Sacituzumab Tirumotecan, or one of the standard chemotherapy treatments. You would have regular visits to the hospital for your treatment sessions and to have tests like blood tests and scans. These tests help the doctors monitor your health and how your cancer is responding to the treatment. There will also be rescue medications available if you need them for any side effects from your treatment.
Throughout the study, the medical team will closely monitor you. You will also have follow-up appointments after your treatment period to see how you are doing in the longer term. The total duration of your involvement in the study would depend on how your treatment is going and how long you remain on the study drug, followed by a period of observation.
Potenzielle Risiken und Vorteile
Standorte (113)
- Hoag Memorial Hospital Presbyterian ( Site 0814)Verifizierte PostleitzahlNewport Beach, Vereinigte Staaten· Rekrutierung
- Sibley Memorial Hospital ( Site 0849)Verifizierte PostleitzahlWashington D.C., Vereinigte Staaten· Rekrutierung
- Emory University Hospital ( Site 0824)Verifizierte PostleitzahlAtlanta, Vereinigte Staaten· Rekrutierung
- Johns Hopkins University ( Site 0843)Verifizierte PostleitzahlBaltimore, Vereinigte Staaten· Rekrutierung
- Dana Farber Cancer Institute ( Site 0783)Verifizierte PostleitzahlBoston, Vereinigte Staaten· Rekrutierung
- Munson Medical Center ( Site 0812)Verifizierte PostleitzahlTraverse City, United States· Rekrutierung
- Morristown Memorial Hospital ( Site 0795)Verifizierte PostleitzahlMorristown, United States· Rekrutierung
- Memorial Sloan Kettering Cancer Center ( Site 0832)Verifizierte PostleitzahlNew York, Vereinigte Staaten· Rekrutierung
- WakeMed Raleigh Campus ( Site 0811)Verifizierte PostleitzahlRaleigh, United States· Rekrutierung
- TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0822)Verifizierte PostleitzahlCincinnati, Vereinigte Staaten· Rekrutierung
- University Hospitals of Cleveland Case Medical Center ( Site 0834)Verifizierte PostleitzahlCleveland, Vereinigte Staaten· Rekrutierung
- Cleveland Clinic - Ohio ( Site 0793)Verifizierte PostleitzahlCleveland, Vereinigte Staaten· Rekrutierung
Häufige Fragen
What is urothelial cancer?
Urothelial cancer is a type of cancer that starts in the cells lining the bladder, ureters, or renal pelvis. It's often called bladder cancer if it starts in the bladder.
What does 'locally advanced or metastatic' mean?
'Locally advanced' means the cancer has grown into nearby tissues but hasn't spread far. 'Metastatic' means the cancer has spread to other parts of the body.
What is a Phase 3 study?
A Phase 3 study is a larger trial that compares a new treatment to existing standard treatments. It aims to confirm if the new treatment is effective and safe for a wider group of people.
Werde ich das neue Medikament auf jeden Fall bekommen?
No, you will be randomly assigned to either receive the new medicine, Sacituzumab Tirumotecan, or one of the standard chemotherapy treatments. It's like flipping a coin for which treatment you get.
What if the treatment isn't working for me?
Your medical team will closely monitor your health and how your cancer responds. If the treatment isn't working or if you experience severe side effects, they will discuss alternative options with you.
Wie Sie mehr erfahren können
Gebührenfreie Nummer
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.